REGISTERED NUMBER: 14583567 (England and Wales)

AUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 1 FEBRUARY 2025 TO 31 JULY 2026

FOR

INAGENE DIAGNOSTICS UK LTD.

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

A M Greenberg

H McCarten

G Soesman

REGISTERED OFFICE:

5th Floor

10 Finsbury Square

London

EC2A 1AF

REGISTERED NUMBER:

14583567 (England and Wales)

SENIOR STATUTORY AUDITOR:

Shahid Hameed FCA FCCA

AUDITORS:

THP Limited

Chartered Accountants

and Statutory Auditors

34-40 High Street

Wanstead

London

E11 2RJ

CURRENT ASSETS

Debtors

4

1,016

4,200

Cash at bank

-

3,561

1,016

7,761

CREDITORS

Amounts falling due within one year

5

-

446,315

NET CURRENT ASSETS/(LIABILITIES)

1,016

(438,554

)

TOTAL ASSETS LESS CURRENT LIABILITIES

1,016

(438,554

)

RESERVES

Retained earnings

1,016

(438,554

)

SHAREHOLDERS' FUNDS

1,016

(438,554

)

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 September 2026 and were signed on its behalf by:

H McCarten - Director

1.	STATUTORY INFORMATION

Inagene Diagnostics UK Ltd. is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements and going concern

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

During the period, the directors of the Company's ultimate parent undertaking made the decision to cease operations and wind down its affairs. Trading was ceased on 31 July 2026 and the directors intend to apply for voluntary strike-off under section 1003 of the Companies Act 2006 following the settlement of all remaining liabilities.

As the directors do not intend the Company to continue in operational existence for the foreseeable future, the going concern basis of accounting is no longer appropriate.

Accordingly, the financial statements have been prepared on an alternative basis. Under this basis, assets are stated at their estimated realisable values and liabilities are stated at the amounts expected to be settled. The directors have considered the impact of the Company's planned closure in determining the carrying value of assets and liabilities at the balance sheet date.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents the amount receivable for goods delivered and services provided, net of returns, discounts and value added taxes.

Revenue is recognised when goods are delivered and services are provided to the customer, such that the risks and rewards of ownership have passed to them.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL (2025 - 1 ).

4.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Trade debtors

-

4,200

VAT

1,016

-

1,016

4,200

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Amounts owed to group undertakings

-

428,897

VAT

-

218

Accrued expenses

-

17,200

-

446,315

6.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal value:

2026

2025

£

£

1

Ordinary

£0.01

0.01

0.01

7.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Shahid Hameed FCA FCCA (Senior Statutory Auditor)

for and on behalf of THP Limited

8.	RELATED PARTY DISCLOSURES

Included in creditors is an amount due to the parent company of £nil (2025: £428,897). This loan was interest free and repayable on demand.

During the year the parent company, Inagene Diagnostics Inc. waived £450,334 (2025: £nil) of the debt due to them.

9.	ULTIMATE CONTROLLING PARTY

The immediate parent company is Inagene Diagnostics Inc. (incorporated in Canada and registered office at 2345 Yonge Street, Suite 802, Toronto, Ontario M4P 2E5). The ultimate parent company is Minett Capital Inc., who are also incorporated in Canada and registered at the same address.

The ultimate controlling party is A M Greenberg.

10.	CHANGE OF ACCOUNTING PERIOD

During the period, the company changed its accounting reference date from 31 January to 31 July in order to align the financial statements with the planned cessation of trading and closure of the company. Accordingly, these financial statements cover the 18 month period ended 31 July 2026. The comparative figures cover the 12 month period ended 31 January 2025 and are therefore not directly comparable.